HWHong-Xia Wang

Hong-Xia Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hong-Xia Wang has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Hui Yang

    Department of Pathology, School of Basic Medical Sciences, Capital Medical University, Beijing, China

    6 shared publications
  • Cui Tian

    Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China

    5 shared publications
  • Nan Li

    Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China

    3 shared publications
  • Wen-Jun Li

    Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China

    3 shared publications
  • Xue Xiao

    Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China

    3 shared publications
  • Yun-Long Zhang

    Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China

    3 shared publications

Latest Publications

  • Attenuation of myocardial ischemia–reperfusion injury in mice through CD80/86 deficiency: improved microvascular obstruction via reduced macrophage and T lymphocyte infiltration

    by Lu Liu, Xiao-Xiao Wang, Si-Xue Wang, Hui Yang, Xue Xiao, Nan Li, Hao-Jiang Chai, Hong-Xia Wang

    Microvascular obstruction (MVO) is a fundamental mechanism underlying the occurrence of no-reflow, which contributes to myocardial ischemia–reperfusion injury (MI/RI). Despite its significance, the precise pathophysiology of MVO remains incompletely understood. In this study, we aim to investigate the role of CD80/86, co-stimulatory molecules crucial for T cell activation, in exacerbating MVO during MI/RI, and elucidate their potential mechanism of action. The results revealed a significant increase in cardiac CD80/86 in mice after I/R treatment. Strikingly, the deletion of CD80/86 greatly improved cardiac function, reduced infarct size, and mitigated apoptosis 24 h after MI/R. Mechanistically, CD80/86 deletion or inhibition led to a reduction in E-selectin expression, subsequently decreasing the infiltration of macrophages and T cells, thereby counteracting MVO and ameliorating the development of no-reflow during MI/RI. In conclusion, our data highlight the crucial involvement of CD80/86 in regulating macrophage and T cells infiltration, leading to the alleviation of MVO and myocardial MI/RI. The insights gained from this study suggest that targeted inhibition of CD80/86 holds promise as a potential therapeutic strategy to protect cardiac function in patients with acute myocardial infarction undergoing reperfusion therapy. Further research in this direction could pave the way for improved treatment options in the management of ischemic heart conditions.


  • Open Access

    CD1d‐Dependent Natural Killer T Cells Mediate Hypertension and Vascular Injury Through Interleukin‐17A

    by Xue Xiao, Cui‐Liu Hou, Yun‐Long Zhang, Hui Yang, Xiao‐Xiao Wang, Hong‐Xia Wang

    Background: Different T‐lymphocyte subsets, including CD1d‐dependent natural killer T (NKT) cells, play distinct roles in hypertension, highlighting the importance of identifying key immune cells for its treatment. This study aimed to determine the unknown effects of CD1d‐dependent NKT cells on hypertension and vascular injury. Methods and Results: Hypertension models were induced in male CD1d knockout (CD1dko), wild‐type, and adoptive bone marrow transfer mice by angiotensin II (Ang II) or deoxycorticosterone acetate salt. Blood pressure was measured by the tail‐cuff system and radiotelemetry. Vascular injury was assessed by histologic studies or aortic ring assay. Inflammation was detected by flow cytometry, quantitative real‐time polymerase chain reaction, or ELISA. Results showed that Ang II infusion significantly reduced CD1d expression and NKT cell numbers in the aorta of mice. CD1dko mice exhibited worsened blood pressure elevation, vascular injury, and inflammatory response induced by Ang II or deoxycorticosterone acetate salt. However, these effects were markedly reversed in wild‐type mice treated with NKT cell–specific activator. Adoptive transfer of CD1dko bone marrow cells to wild‐type mice also significantly worsened Ang II–induced responses. Mechanistically, CD1dko increased Ang II–induced interleukin‐6 production and activated signal transducer and activator of transcription 3 and orphan nuclear receptor γ, subsequently inducing interleukin‐17A production. Neutralizing interleukin‐17A partially reversed Ang II–induced hypertension and vascular injury in CD1dko mice. In addition, levels of NKT cells were lower in the blood of patients with hypertension (n=57) compared with normotensive individuals (n=87). Conclusions: These findings reveal a previously unknown role for CD1d‐dependent NKT cells in hypertension and vascular injury, indicating that NKT cell activation could be a promising therapeutic target for hypertension.


  • Open Access

    Intravenous Alteplase Treatment of Acute Ischemic Stroke Patients Exhibiting Mild Neurological Deficits

    by Jing Sun, Hongxia Wang, Mengjiao Sun, Qinfang Xie, Ning Liu, Manxia Wang

    Alteplase is increasingly used for treating ischemic stroke cases with low NIHSS scores, but the guidelines and evidence regarding outcomes are lacking. So, the authors conducted an updated meta-analysis to better understand the effects of alteplase for the treatment of acute mild ischemic stroke. PubMed, Cochrane, EMBASE were systematically explored for all relevant investigations published as in September 2021. Study quality was assessed as per the Cochrane system criteria, and Stata 15.1 was utilised to carry out a meta-analysis. In total, 16 trials incorporating 5,846 patients were analysed (1,926 and 3,920 cases in the rt-PA and non-thrombolytic groups, respectively). The main outcome measure revealed that the treatment of rt-PA was correlated with better odds of a modified Rankin Scale (mRS) score of 0-1 relating to the non-thrombolytic group (OR = 1.12, 95% CI = 1.02-1.23, p <0.05), and with moderate heterogeneity (I2 = 0.0%, p = 0.930). For the secondary study outcomes, symptomatic intracranial hemorrhage incidence was 4.46 times greater in the group of rt-PA, relating to the non-thrombolytic group (OR = 4.46, 95% CI = 2.75-7.23, p 0.05). No significant heterogeneity was detected in secondary study outcomes. Subgroup analysis showed that the function outcomes was the best within 3-4.5 hours; and the risk and mortality of sICH were the lowest within 3-4.5 hours. Intravenous rt-PA administration is associated with improved functional outcomes at three months after the stroke in mild ischemic stroke patients. Key Words: Acute ischemic stroke, Mild, Alteplase, Meta-analysis.


  • Open Access

    Inhibition of CXCR2 alleviates the development of abdominal aortic aneurysm in Apo E-/- mice

    by Bo Sun, Fangda Li, Song Lai, Xu Zhang, Hongxia Wang, Yuan Li, Wei Wang, Yuexin Chen, Bao Liu, Yuehong Zheng

    Purpose To investigate the relationship between atherosclerotic abdominal aortic aneurysm (AAA) and CXC chemokine receptor type 2 (CXCR2). Methods Mouse AAA model was established by embedding angiotensin-II pump (1000 ng/kg/min) in ApoE-/- mice. Mice were received SB225002, a selective CXCR2 antagonist, for treatment. Blood pressure was recorded, and CXCR2+ macrophages were examined by flow cytometry analysis. Terminal-deoxynucleotidyl transferase mediated nick end labeling (TUNEL) staining was performed to detect cell apoptosis of abdominal aortic aneurysms. Macrophages were isolated from ApoE-/- mice and treated with Ang II and/or SB225002. Dihydroethidium staining was carried out to determine reactive oxygen species (ROS) activity. Enzyme-linked immunosorbent assay (ELISA) was performed to determine the production of IL-1β and TNF-α. The corresponding gene expressions were measured using real-time polymerase chain reaction (PCR), western blot, and immunohistochemistry staining. Results We found that Ang II activated the expression of CXCR2 in monocytes during the formation of AAA. Inhibition of CXCR2 significantly reduced the size of AAA, attenuated inflammation and phenotypic changes in blood vessels. Ang II-induced macrophages exhibited elevated ROS activity, and elevated levels of 1β and TNF-α, which were then partly abolished by SB225002. Conclusions CXCR2 plays an important role in AAA, suggesting that inhibiting CXCR2 may be a new treatment for AAA.


  • Open Access

    Tripartite motif 10 regulates cardiac hypertrophy by targeting the PTEN/AKT pathway

    by Hui Yang, Xiao‐Xiao Wang, Chun‐Yu Zhou, Xue Xiao, Cui Tian, Hui‐Hua Li, Chun‐Lin Yin, Hong‐Xia Wang

    The pathogenesis of cardiac hypertrophy is tightly associated with activation of intracellular hypertrophic signalling pathways, which leads to the synthesis of various proteins. Tripartite motif 10 (TRIM10) is an E3 ligase with important functions in protein quality control. However, its role in cardiac hypertrophy was unclear. In this study, neonatal rat cardiomyocytes (NRCMs) and TRIM10‐knockout mice were subjected to phenylephrine (PE) stimulation or transverse aortic constriction (TAC) to induce cardiac hypertrophy in vitro and in vivo, respectively. Trim10 expression was significantly increased in hypertrophied murine hearts and PE‐stimulated NRCMs. Knockdown of TRIM10 in NRCMs alleviated PE‐induced changes in the size of cardiomyocytes and hypertrophy gene expression, whereas TRIM10 overexpression aggravated these changes. These results were further verified in TRIM10‐knockout mice. Mechanistically, we found that TRIM10 knockout or knockdown decreased AKT phosphorylation. Furthermore, we found that TRIM10 knockout or knockdown increased ubiquitination of phosphatase and tensin homolog (PTEN), which negatively regulated AKT activation. The results of this study reveal the involvement of TRIM10 in pathological cardiac hypertrophy, which may occur by prompting of PTEN ubiquitination and subsequent activation of AKT signalling. Therefore, TRIM10 may be a promising target for treatment of cardiac hypertrophy.


  • Open Access

    Impact of Salt Substitute and Stepwise Reduction of Salt Supply on Blood Pressure in the Elderly in Nursing Homes (DECIDE-Salt Trial): Protocol and Baseline Characteristics (P13-022-19)

    by Aoming Jin, Xiangxian Feng, Ruijuan Zhang, Hongxia Wang, Qianku Qiao, Lin Feng, Pei Gao, Hai Fang, Bruce Neal, Kiang Liu, et al.

    The aim of this study is to evaluate efficacy, safety, and cost-effectiveness of two sodium reduction strategies, salt substitution and stepwise reduction of salt supply, separately or in combination, on blood pressure (BP) in the elderly in nursing homes in northern China. The study is a cluster randomized controlled trial with a two-by-two factorial design conducted in four areas from three northern Chinese provinces. Within each area, nursing homes were randomly assigned (1:1:1:1) to four groups: (1) both replacing normal salt with salt substitute (SS) and training the nursing home manager to reduce 5–10% of salt supply every 3 months (stepwise reduction of salt supply, SRSS), (2) SS only (no SRSS), (3) SRSS only (no SS), or (4) neither SS nor SRSS (control). With a sample size of 1080, 270 in each group, the study would have 80% power to detect a net reduction of 3.0 mmHg in systolic BP, assuming that the standard deviation is 18 mmHg, α = 0.05, intraclass correlation coefficient = 0.02, number of clusters = 36, and participants loss to follow up = 20%. The study began in late 2017 and the interventions will last for two years. The primary outcome will be the changes in mean systolic BP from baseline to 24 months, analyzed by a generalized estimating equations extension of the linear regression model to account for cluster effect. The secondary outcomes will include changes in diastolic BP, incidence of hypertension, 24-hour urinary sodium and potassium excretions, all-cause mortality and incidence of hyperkalemia. Economic evaluations will be conducted as well. A total of 48 nursing homes were recruited in the study. The baseline examination has been completed. A total of 1598 study participants aged 55 to 102 years old were enrolled. The demographical characteristics of the study population, including baseline systolic and diastolic BP, are shown in Table 1. The study is well powered to evaluate the effect of the three study interventions in lowering systolic BP in the elderly. It is expected to provide solid evidence for policy development regarding sodium reduction strategies in prevention and control of hypertension and its related diseases in the elderly. The study is supported by National Key R&D Program of China.

  • Open Access

    The immunoproteasome catalytic β5i subunit regulates cardiac hypertrophy by targeting the autophagy protein ATG5 for degradation

    by Xin Xie, Hai-Lian Bi, Song Lai, Yun-Long Zhang, Nan Li, Hua-Jun Cao, Ling Han, Hong-Xia Wang, Hui-Hua Li

    Immunoproteasome subunit β5i regulates cardiac hypertrophy.


  • Chemokine (C–X–C motif) receptor 2 blockade by SB265610 inhibited angiotensin II-induced abdominal aortic aneurysm in Apo E−/− mice

    by Hao Nie, Hong-Xia Wang, Cui Tian, Hua-Liang Ren, Fang-Da Li, Chao-Yu Wang, Hui-Hua Li, Yue-Hong Zheng

    Inflammation plays a critical role in the development of abdominal aortic aneurysm (AAA). Chemokine receptor CXCR2 mediates inflammatory cell chemotaxis in several diseases. However, the role of CXCR2 in AAA and the underlying mechanisms remain unknown. In this study, we found that the CXCR2 expressions in AAA tissues from human and angiotensin II (Ang II)-infused apolipoprotein E knockout (Apo E−/−) mice were significantly increased. The pharmacological inhibition of CXCR2 (SB265610) markedly reduced Ang II-induced AAA formation. Furthermore, SB265610 treatment significantly reduced collagen deposition, elastin degradation, the metal matrix metalloprotease expression and accumulation of macrophage cells. In conclusion, these results showed CXCR2 plays a pathogenic role in AAA formation. Inhibition of CXCR2 pathway may represent a novel therapeutic approach to treat AAA.


  • CD1d-dependent natural killer T cells attenuate angiotensin II-induced cardiac remodelling via IL-10 signalling in mice

    by Hong-Xia Wang, Wen-Jun Li, Cui-Liu Hou, Song Lai, Yun-Long Zhang, Cui Tian, Hui Yang, Jie Du, Hui-Hua Li

    Aims: CD1d is a member of the cluster of differentiation 1 (CD1) family of glycoproteins expressed on the surface of various antigen-presenting cells, which is recognized by natural killer T (NKT) cells. CD1d-dependent NKT cells play an important role in immune-mediated diseases; but the role of these cells in regulating cardiac remodelling remains unknown. Methods and results: Cardiac remodelling was induced by angiotensin (Ang) II infusion for 2 weeks. Ang II-induced increase in hypertension, cardiac performance, hypertrophy and fibrosis, inflammatory response, and activation of the NF-kB and TGF-β1/Smad2/3 pathways was significantly aggravated in CD1d knockout (CD1dko) mice compared with wild-type (WT) mice, but these effects were markedly abrogated in WT mice treated with α-galactosylceramide (αGC), a specific activator of NKT cells. Adoptive transfer of CD1dko bone marrow cells to WT mice further confirmed the deleterious effect of CD1dko. Moreover, IL-10 expression was significantly decreased in CD1dko hearts but increased in αGC-treated mice. Co-culture experiments revealed that CD1dko dendritic cells significantly reduced IL-10 mRNA expression from NKT cells. Administration of recombinant murine IL-10 to CD1dko mice improved hypertension, cardiac performance, and adverse cardiac remodelling induced by Ang II, and its cardioprotective effect was possibly associated with activation of STAT3, and inhibition of the TGF-β1 and NF-kB pathways. Conclusion: These findings revealed a previously undefined role for CD1d-dependent NKT cells in Ang II-induced cardiac remodelling, hence activation of NKT cells may be a novel therapeutic target for hypertensive cardiac disease.